Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesoFAP CAR-TEAM
- Development stage
- Preclinical
- Lead developer
- Massachusetts General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
mesoFAP CAR-TEAM is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC). These T cells are engineered to express a CAR targeting mesothelin and to simultaneously secrete a T-cell-engaging molecule (TEAM). The TEAM is a bispecific antibody-like molecule that binds to fibroblast activation protein (FAP) on cancer-associated fibroblasts (CAF) and CD3 on T cells. This dual-targeting strategy aims to eliminate both the tumor cells and the immunosuppressive tumor stroma, thereby enhancing the efficacy of the CAR-T cells in the thick stroma characteristic of pancreatic cancer.
- Other names
- mesoFAP CAR-TEAM cells
02
Targets
MesothelinFAP (Fibroblast activation protein alpha)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on mesoFAP CAR-TEAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesoFAP CAR-TEAM.